This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Coronary computed tomography angiography (CCTA) is cheaper, easier to use and its results are easier to understand than Intravascular ultrasound (IVUS), making it ideal for clinical trials of cardi
GE HealthCare (GEHC) reported a 1% growth in existing operation revenues and an increase in profitability in its second quarter of 2024, citing solid performance in its Pharmaceutical Diagnostics segment. For the period (end-September 30), GEHC had total revenues of $4.86 billion, flat compared with $4.82 billion in the same period last year.
The research will produce technical feedback to assist GEHC in assessing the system’s reconstruction methods, image presentation workflow, and clinical benefits for specific pathologies and disease types. Other ultrasound scanners on display included GEHC’s Logiq E10, Fortis, Invenia ABUS 2.0, MRI GEHC unveiled Signa Champion, a 1.5-tesla,
milla1cf Fri, 06/21/2024 - 20:24 June 21, 2024 — GE HealthCare , a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, and MediView XR Inc., Proceduralists must refer to standard of care imaging and prioritize clinical experience and/or judgment when using the OmnifyXR system.
announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio. This includes continuing to grow MIM Software’s offerings for end-to-end standardization across large healthcare system fleets.
Marco Campione brings more than 25 years of experience from GE HealthCare, where he most recently served as Executive Director and Global Head of Contrast Media, General Manager Pharmaceutical Diagnostics North America and President GE HealthCare Inc., according to a written statement announcing the appointment. “I
He ended his tenure as President and CEO of GE Healthcare Systems in the United States and Canada, where he had responsibility for the core businesses of Imaging, Ultrasound, Life Care Solutions, and Enterprise Digital Solutions. Cooper spent nearly 30 years at GE, where he successfully led several business units.
This is a significant milestone for the clinical trial that will help determine whether contrast-enhanced mammography (CEM) improves breast cancer detection and reduces false-positive exams in women with dense breasts. Combined screening with mammography and ultrasound in a population-based screening program. Available at: [link].
Sadowski said that MR can be avoided altogether by using ultrasound, CT, or molecular imaging. The ACR and the FDA recommend immediate hemodialysis directly from the MR scanner," Kanal said, plus another dialysis session within 24 hours if it's clinically safe to do so.
Article: PATCH-Trauma Investigators and ANZICS Clinical Trial Group. PMID: 37314244 Clinical Question: In advanced trauma systems, does prehospital administration of TXA increase the rate of survival with a favorable neurologic outcome in patients at risk for trauma-induced coagulopathy? Prehospital Tranexamic Acid for Severe Trauma.
A regular supply chain of affordable medicines and pharmaceuticals is also not in place because of limited indigenous production of drugs and scarce medical research facilities. The operations team would coordinate for any additional information, be it clinical or image related and pass it onto the clinical team.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content